Discontinued — last reported Q4 '21
An increase may signal anticipation of higher sales or supply chain buffering, while a decrease may signal inventory liquidation or supply constraints.
Represents the total value of finished goods, work-in-progress, and raw materials specifically allocated to the producti...
Peers in the biopharmaceutical sector typically report this as product-specific inventory within their segment disclosures or notes to the financial statements.
biib_segment_aduhelm_inventory| Q4 '21 | |
|---|---|
| Value | $223.00M |